Trials / Recruiting
RecruitingNCT04962867
NCCH2006/MK010 Trial (FORTUNE Trial)
Multicenter Investigator-initiated Phase II Trial of E7090 in Patients With Advanced or Recurrent Solid Tumor With Fibroblast Growth Factor Receptor (FGFR) Gene Alteration (FORTUNE Trial)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- Sponsor
- National Cancer Center, Japan · Other Government
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label, multicenter, investigator-initiated Phase 2 trial to evaluate the efficacy and safety of E7090 in patients with advanced or recurrent solid tumors harboring FGFR genetic alterations (including fusion, mutation, amplification).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E7090 | 140 mg of E7090 is orally administered once daily. |
Timeline
- Start date
- 2021-06-15
- Primary completion
- 2028-03-31
- Completion
- 2028-03-31
- First posted
- 2021-07-15
- Last updated
- 2025-10-03
Locations
7 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04962867. Inclusion in this directory is not an endorsement.